Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

971 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Spatiotemporal characteristics of fibroblasts-dependent cancer cell invasion.
Miyashita T, Omori T, Nakamura H, Sugano M, Neri S, Fujii S, Hashimoto H, Tsuboi M, Ochiai A, Ishii G. Miyashita T, et al. Among authors: omori t. J Cancer Res Clin Oncol. 2019 Feb;145(2):373-381. doi: 10.1007/s00432-018-2798-y. Epub 2018 Nov 23. J Cancer Res Clin Oncol. 2019. PMID: 30470886
Prognostic impact of artificial intelligence-based volumetric quantification of the solid part of the tumor in clinical stage 0-I adenocarcinoma.
Kawaguchi Y, Shimada Y, Murakami K, Omori T, Kudo Y, Makino Y, Maehara S, Hagiwara M, Kakihana M, Yamada T, Park J, Matsubayashi J, Ohira T, Ikeda N. Kawaguchi Y, et al. Among authors: omori t. Lung Cancer. 2022 Aug;170:85-90. doi: 10.1016/j.lungcan.2022.06.007. Epub 2022 Jun 11. Lung Cancer. 2022. PMID: 35728481
Prognostic impact of dysphagia scores in patients with advanced resectable esophageal cancer who underwent radical esophagectomy after preoperative treatment.
Sugase T, Kanemura T, Matsuura N, Ushimaru Y, Masuike Y, Yanagimoto Y, Mori R, Kitakaze M, Amisaki M, Kubo M, Mukai Y, Komatsu H, Sueda T, Kagawa Y, Nishimura J, Wada H, Yasui M, Omori T, Miyata H. Sugase T, et al. Among authors: omori t. J Gastrointest Surg. 2024 Sep 4:S1091-255X(24)00599-7. doi: 10.1016/j.gassur.2024.08.031. Online ahead of print. J Gastrointest Surg. 2024. PMID: 39241945
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial.
Boku N, Omori T, Shitara K, Sakuramoto S, Yamaguchi K, Kato K, Kadowaki S, Tsuji K, Ryu MH, Oh DY, Oh SC, Rha SY, Lee KW, Chung IJ, Sym SJ, Chen LT, Chen JS, Bai LY, Nakada T, Hagihara S, Makino R, Nishiyama E, Kang YK. Boku N, et al. Among authors: omori t. Gastric Cancer. 2024 Aug 20. doi: 10.1007/s10120-024-01535-0. Online ahead of print. Gastric Cancer. 2024. PMID: 39162872
971 results